HAEMONETICS CORP — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2021-02-04

Reporting Person: Dockendorff Charles J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-04	Common Stock	M	12180	$35.5025	Acquired	25935	Direct
2021-02-04	Common Stock	S	12180	$134.53	Disposed	13755	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Non-qualified Stock Option (Right to Buy)	$35.5025	M	12180	Disposed	2021-07-23	Common Stock (12180)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8568	Indirect

Footnotes

F1: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F2: This number includes unvested restricted stock units previously reported.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.14 to $135.00, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: Reflects shares held by a grantor retained annuity trust, of which Mr. Dockendorff is the sole trustee, subsequent to an exempt transfer by Mr. Dockendorff.

F5: Options vest 100% on the first anniversary of the date of grant.